Antitumor activity was modest overall (ORR 12.1%), while ORR at the recommended phase 2 dose was 21.1% with only 5.3% primary progression versus 33.7% previously reported. Efficacy signals were ...
Targeted Oral Therapies in Progressive Small Bowel Neuroendocrine Tumor: Everolimus and Cabozantinib
Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results